rs28937879
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The NM_021615.5(CHST6):āc.599T>Gā(p.Leu200Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000306 in 1,611,220 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Pathogenic (ā ā ).
Frequency
Consequence
NM_021615.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CHST6 | NM_021615.5 | c.599T>G | p.Leu200Arg | missense_variant | 3/3 | ENST00000332272.9 | NP_067628.1 | |
CHST6 | NR_163480.1 | n.733+2587T>G | intron_variant | |||||
CHST6 | NR_163481.1 | n.577+2587T>G | intron_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CHST6 | ENST00000332272.9 | c.599T>G | p.Leu200Arg | missense_variant | 3/3 | 3 | NM_021615.5 | ENSP00000328983.4 |
Frequencies
GnomAD3 genomes AF: 0.000210 AC: 32AN: 152192Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000225 AC: 55AN: 244732Hom.: 0 AF XY: 0.000225 AC XY: 30AN XY: 133274
GnomAD4 exome AF: 0.000316 AC: 461AN: 1459028Hom.: 0 Cov.: 31 AF XY: 0.000314 AC XY: 228AN XY: 725996
GnomAD4 genome AF: 0.000210 AC: 32AN: 152192Hom.: 0 Cov.: 33 AF XY: 0.000202 AC XY: 15AN XY: 74366
ClinVar
Submissions by phenotype
Macular corneal dystrophy Pathogenic:8
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Sep 10, 2024 | Variant summary: CHST6 c.599T>G (p.Leu200Arg) results in a non-conservative amino acid change located in the Sulfotransferase domain (IPR000863) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00022 in 244732 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in CHST6 causing Macular Corneal Dystrophy (0.00022 vs 0.0013), allowing no conclusion about variant significance. c.599T>G has been reported in the literature as a biallelic genotype in multiple individuals affected with Macular Corneal Dystrophy (example, El Ashry_2002, Safari_2020, Souzeau_2022). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 11818380, 32472422, 35985662). ClinVar contains an entry for this variant (Variation ID: 5075). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Jun 28, 2016 | The p.Leu200Arg variant in CHST6 has been reported in at least 17 individuals wi th macular corneal dystrophy who also tested positive for a reduction in keratin sulfate consistent with CHST6 deficiency (14 compound heterozygotes, 1 homozygo te and 2 heterozygotes) (El-Ashry 2002, El-Ashry 2005, Abbruzzese 2004, Klintwor th 2006, Liskova 2008). This variant has been identified in 0.03% (30/115,942) o f chromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstit ute.org; dbSNP rs28937879). Although it has been seen in the general population, its frequency is low enough to be consistent with a recessive carrier frequency . In summary, this variant meets our criteria to be classified as pathogenic for macular corneal dystrophy in an autosomal recessive manner based upon its biall elic occurrence in affected individuals and functional evidence. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Mar 01, 2004 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Feb 24, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genetics and Molecular Pathology, SA Pathology | Oct 13, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 16, 2021 | This sequence change replaces leucine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 200 of the CHST6 protein (p.Leu200Arg). This variant is present in population databases (rs28937879, gnomAD 0.05%). This missense change has been observed in individuals with macular corneal dystrophy (PMID: 11818380, 16568029, 32472422). It has also been observed to segregate with disease in related individuals. This variant is also known as 1291T>G. ClinVar contains an entry for this variant (Variation ID: 5075). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 09, 2019 | The CHST6 c.599T>G (p.Leu200Arg) missense variant has been reported in at least seven studies in which it is identified in a total of 37 individuals with macular corneal dystrophy (MCD) type I or II from 31 families, including in seven in a homozygous state (two of whom are related); 19 in a compound heterozygous state (two of whom are related); and 11 in a heterozygous state (two of whom are related) (El-Ashry et al. 2002; Aldave et al. 2004; Klintworth et al. 2006; Gruenauer-Kloevekorn et al. 2008; Liskova et al. 2008; Dudakova et al. 2014; Nowinska et al. 2014). The p.Leu200Arg variant was detected in a heterozygous state in one of 694 control chromosomes and is reported at a frequency of 0.000471 in the European (non-Finnish) population of the Genome Aggregation Database. The Leu200 residue is noted to be highly conserved. Based on the collective evidence, the p.Leu200Arg variant is classified as pathogenic for macular corneal dystrophy. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Pathogenic, criteria provided, single submitter | clinical testing | MGZ Medical Genetics Center | May 09, 2022 | - - |
Macular corneal dystrophy, type II Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Mar 01, 2004 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Sep 01, 2019 | - - |
CHST6-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Aug 27, 2024 | The CHST6 c.599T>G variant is predicted to result in the amino acid substitution p.Leu200Arg. This variant has been reported along with one or more other CHST6 variants in multiple individuals with macular corneal dystrophy (El-Ashry et al. 2002. PubMed ID: 11818380; Klintworth et al. 2006. PubMed ID: 16568029; Weiss et al. 2008. PubMed ID: 19337156; Safari et al. 2020. PubMed ID: 32472422), and is considered a mutation hot-spot (Aldave et al. 2004. PubMed ID: 15013869). This variant is reported in 0.047% of alleles in individuals of European (Non-Finnish) descent in gnomAD. This variant is interpreted as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at